Compare Payoneer Global Inc (PAYO) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Payoneer Global Inc vs 10X Genomics Inc — how do they compare? Payoneer Global Inc trades at $7.15 (market cap $2.43B), while 10X Genomics Inc trades at $81.93 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 4.1× Payoneer Global Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Payoneer Global Inc for 61 Days and 10X Genomics Inc for 92 Days on average.
| PAYO | TXG | |
|---|---|---|
Market Cap | $2.43B | $10.07B |
Volume | 1,342,701 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $7.18 | $97.74 |
52-Week Low | $4.27 | $11.48 |
Typical Hold Time | 61 Days | 92 Days |
Enterprise Value | $2.17B | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Payoneer Global (PAYO) trades at $7.15, down slightly by 0.14% with a bullish technical signal from moving averages. The company reported Q2 2026 earnings of $0.02 per share, missing estimates, but revenue grew 10% excluding interest. Recent news highlights Payoneer's renewed partnership with Etsy through 2029 and the company's agreement to be acquired by Nuvei announced in June 2026. Analyst sentiment remains positive with 60% buy ratings despite recent earnings volatility.
The acquisition by Nuvei creates near-term upside potential, but execution risks and margin compression pose challenges. Revenue growth remains solid at 15% volume growth year-over-year, though net income margin has declined from 16.8% in 2024 to 5.8% projected for 2026. The stock's valuation at 51x P/E appears stretched relative to earnings growth, suggesting cautious optimism is warranted.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
